Medicines360

29 articles about Medicines360

• Medicines360 Appoints Andrea Olariu, MD, PhD as Chief Executive Officer

  5/30/2023

  Medicines360, a mission-driven nonprofit women's health pharmaceutical organization, announced that its Board of Directors has named Andrea Olariu, MD, PhD as Chief Executive Officer, effective immediately.

• 

  BioSpace Movers & Shakers, July 9

  7/9/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Medicines360 Appoints Tina Raine-Bennett, MD, MPH, FACOG, as Chief Executive Officer

  7/6/2021

  Medicines360, a global nonprofit women's health pharmaceutical organization, has appointed Tina Raine-Bennett , MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search.

• Medicines360 Appoints Rolf Jansen as Vice President of Development and Manufacturing

  7/17/2020

  Medicines360, a global nonprofit women's health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty yea

• Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.

  5/6/2019

  Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting

• Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

  9/6/2018

  Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs)

• Medicines360 and Direct Relief Partner to Expand Access for U.S. Women

  8/20/2018

  Partnership will provide free hormonal IUDs to underserved women across the country

• Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study

  4/30/2018

  Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting

• FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

  2/22/2018

  Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360 today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's supplemental New Drug Application (sNDA)

• Study Finds Z-CAN Program, Supported by Medicines360, Increased Use of LARCs by Women in Puerto Rico During Zika Outbreak

  1/29/2018

  Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today highlighted a new report published in The Lancet Public Health.

• FDA Approves Medicines360's sNDA For LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Four Years

  8/7/2017

• Medicines360 And Allergan Present Four-Year Multi-Center Pivotal Trial Data Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg At The 2017 American College of Obstetricians and Gynecologist Meeting

  5/9/2017

• Medicines360 And Allergan Announce Partnership With Health Centers To Help Address Unintended Pregnancies In Areas Impacted By Zika

  2/15/2017

• Medicines360 And Allergan Announce Study Publication Evaluating Pelvic Infection Risk Following Same-Day Sexually Transmitted Infection Testing And Liletta (Levonorgestrel-Releasing Intrauterine System) 52 Mg Placement

  11/16/2016

• Medicines360 And Population Services International Announce New Partnership To Expand Access To Hormonal IUDs To Women In Africa

  9/28/2016

• Allergan And Medicines360 Announce Launch Of New LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 Mg Single-Handed Inserter

  9/14/2016

• Medicines360 And Allergan Announce Publication Of Levonorgestrel Release Rates Over Five Years With The LILETTA 52 Mg Intrauterine System In 'Contraception'

  9/7/2016

• Allergan And Medicines360 Announce Donation Of Intrauterine Devices (IUD) To The CDC Foundation To Help Address Microcephaly Impact From Zika Virus In Puerto Rico

  6/1/2016

• Medicines360 and Camargo Pharmaceutical Services Gain FDA Approval for Intrauterine Contraceptive Device

  1/19/2016

• Medicines360 Announces New Partnership With Marie Stopes International To Expand Access To Its Hormonal IUD To Women In Kenya, East Africa

  12/7/2015